KRAS G12C & KRAS G12D by Tumour
Showing the single result
KRAS inhibitors-Market opportunity, Epidemiology & Market Forecast, Pipeline and Competitive Analysis, 2020-2030$2,275.00 – $6,825.00
This KRAS report covers the KRAS market opportunity providing key competitive analysis, 37 companies with pipeline drug profiles, clinical trials, upcoming events, other Developments (Collaborations Details, Funding, etc.), Epidemiology forecast of Cancers with KRAS mutation and % of mutation frequency, licensing and deals, as well as presenting market forecast from 2019 to 2030.